195940 - HK inno.N Corporation

195940 Summary
Biopharma
Stock Price & Overview
₩42,050 +300 (+0.72%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩42,050  ≈ US$30  ·  Market cap ₩1.2tn (≈ $851m)

Material matter affecting investment judgment (clinical trial plan approval)

kstock has not written this one up. The title above is a translation of the Korean form name; the filing itself is on DART, in Korean.

Read the original on DART ↗ Korean. DART is Korea's electronic disclosure system, run by the Financial Supervisory Service — the filing equivalent of EDGAR.
Korean form name: 투자판단관련주요경영사항(임상시험계획승인신청등결정) (경증에서 중등증 아토피 피부염 치료 후보물질 IN-115314 임상 1b상 임상시험계획(IND) 미국 식품의약국(FDA) 승인)